Aspects concerning patient adherence to anti‑TNFα therapy in psoriasis: A decade of clinical experience

Mocanu,Madalina; Toader,Mihaela‑Paula; Rezus,Elena; Taranu,Tatiana

doi:10.3892/etm.2019.8008

Aspects concerning patient adherence to anti‑TNFα therapy in psoriasis: A decade of clinical experience

Authors:
- Madalina Mocanu
- Mihaela‑Paula Toader
- Elena Rezus
- Tatiana Taranu
View Affiliations

Affiliations: Dermatology Clinic, Railways University Hospital Iasi, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700506 Iasi, Romania, Rheumatology Clinic, University Rehabilitation Hospital, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700115 Iasi, Romania
Published online on: September 16, 2019 https://doi.org/10.3892/etm.2019.8008
Pages: 4987-4992
Copyright: © Mocanu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑adherence to psoriasis treatment has an important impact in controlling chronic disease evolution and the occurrence of systemic comorbidities. Biologic therapy represents a revolutionary treatment, many of the undesirable psychological and socio‑economical consequences of conventional topical or systemic therapies being avoided. Nevertheless, the discontinuation of biological therapy may occur due to facts related to the patient, to the lack of good communication between the patient and the physician or to the adverse or paradoxical reactions. We studied the non‑adherence reasons to anti‑TNFα agents (Infliximab, Adalimumab, Etanercept) used for treating 84 cases with moderate‑severe psoriasis. The results of our study over the past 10 years showed a 76.2% adherence rate, lowest in patients treated with Etanercept (70.9%). Relative to the anti‑TNF agent used, the highest adherence rate was recorded in Adalimumab (80.8%), followed by Infliximab (76.5%) and Etanercept (70.9%). We have noticed differences between the rates of adhesion to therapy with different anti‑TNFα agents, but with no statistical significance. The main adverse effects that occurred during anti‑TNFα therapy were: local reaction to the drug, mild infectious events, allergic reactions, cardiotoxicity, alopecia areata, pancreatitis, eosinophilia, thrombocytopenia. Anti‑TNF therapy was discontinued in one case of endocarditis, one case with tuberculous laryngitis and another one with polydiscitis (Adalimumab), a case of colon cancer and one of pregnancy (Etanercept) and one paradoxical reaction (Infliximab).

View Figures

View References

1	Schadler ED, Ortel B and Mehlis SL: Biologics for the primary care physician: Review and treatment of psoriasis. Dis Mon. 65:51–90. 2019. View Article : Google Scholar : PubMed/NCBI
2	Căruntu C, Boda D, Căruntu A, Rotaru M, Baderca F and Zurac S: In vivo imaging techniques for psoriatic lesions. Rom J Morphol Embryol. 55 (Suppl):1191–1196. 2014.PubMed/NCBI
3	Batani A, Brănișteanu DE, Ilie MA, Boda D, Ianosi S, Ianosi G and Căruntu C: Assessment of dermal papillary and microvascular parameters in psoriasis vulgaris using in vivo reflectance confocal microscopy. Exp Ther Med. 15:1241–1246. 2018.PubMed/NCBI
4	Negrei C, Ginghină O, Căruntu C, Burcea Dragomiroiu GTA, Jinescu G and Boda D: Investigation relevance of methotrexate polyglutamates in biological systems by high performance liquid chromatography. Rev Chim. 66:766–768. 2015.
5	Negrei C, Arsene AL, Toderașcu CD, Boda D and Ilie M: Acitretin treatment in psoriasis may influence the cell membrane fluidity. Farmacia. 60:767–771. 2012.
6	Negrei C, Căruntu C, Ginghina O, Dragomiroiu GTAB, Toderascu CD and Boda D: Qualitative and quantitative determination of methotrexate polyglutamates in erythrocytes by high performance liquid chromatography. Rev Chim. 66:607–610. 2015.
7	Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, et al: Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis. Cochrane Database Syst Rev. 12:CD0115352017.PubMed/NCBI
8	Olteanu R, Zota A and Constantin M: Biosimilars: An update on clinical trials (review of published and ongoing studies. Acta Dermatovenerol Croat. 25:57–66. 2017.PubMed/NCBI
9	Olteanu R, Constantin MM, Zota A, Dorobantu DM, Constantin T, Serban ED, Balanescu P, Mihele D and Gheuca-Solovastru L: Original clinical experience and approach to treatment study with interleukine 12/23 inhibitor in moderate-to-severe psoriasis patients. Farmacia. 64:918–921. 2016.
10	Zambrano R, Duitama JF, Posda JI and Flórez JF: Perception of adherence to treatment among patients with cardiovascular risk factors. Rev Fac Nac Salud Publica. 30:163–174. 2012.
11	Tatu AL and Nwabudike LC: Metoprolol-associated onset of psoriatic arthropathy. Am J Ther. 24:e370–e371. 2017. View Article : Google Scholar : PubMed/NCBI
12	Sabate E: Adherence to Long-Term Therapies: Evidence for ActionWorld Health Organization; Geneva: 2003, https://www.who.int/chp/knowledge/publications/adherence_report/en/
13	Boda D, Negrei C, Nicolescu F and Balalau C: Assessment of some oxidative stress parameters in methotrexate treated psoriasis patients. Farmacia. 62:704–710. 2014.
14	Radtke MA and Augustin M: Economic considerations in psoriasis management. Clin Dermatol. 26:424–431. 2008. View Article : Google Scholar : PubMed/NCBI
15	Ross C, Marshman G, Grillo M and Stanford T: Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective. Australas J Dermatol. 57:137–140. 2016. View Article : Google Scholar : PubMed/NCBI
16	Raval K, Lofland JH, Waters H and Piech CT: Disease and treatment burden of psoriasis: Examining the impact of biologics. J Drugs Dermatol. 10:189–196. 2011.PubMed/NCBI
17	Schaarschmidt ML, Kromer C, Herr R, Schmieder A, Goerdt S and Peitsch WK: Treatment satisfaction of patients with psoriasis. Acta Derm Venereol. 95:572–578. 2015. View Article : Google Scholar : PubMed/NCBI
18	Zschocke I, Ortland C and Reich K: Evaluation of adherence predictors for the treatment of moderate to severe psoriasis with biologics: The importance of physician-patient interaction and communication. J Eur Acad Dermatol Venereol. 31:1014–1020. 2017. View Article : Google Scholar : PubMed/NCBI
19	Doshi JA, Takeshita J, Pinto L, Li P, Yu X, Rao P, Viswanathan HN and Gelfand JM: Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population. J Am Acad Dermatol. 74:1057–1065.e4. 2016. View Article : Google Scholar : PubMed/NCBI
20	Umezawa Y, Nobeyama Y, Hayashi M, Fukuchi O, Ito T, Saeki H and Nakagawa H: Drug survival rates in patients with psoriasis after treatment with biologics. J Dermatol. 40:1008–1013. 2013. View Article : Google Scholar : PubMed/NCBI
21	Gniadecki R, Kragballe K, Dam TN and Skov L: Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol. 164:1091–1096. 2011. View Article : Google Scholar : PubMed/NCBI
22	Kim WB, Marinas JE, Qiang J, Shahbaz A, Greaves S and Yeung J: Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: A Canadian multicenter retrospective study. J Am Acad Dermatol. 73:237–241. 2015. View Article : Google Scholar : PubMed/NCBI
23	Kaushik SB and Lebwohl MG: Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections. J Am Acad Dermatol. 80:43–53. 2019. View Article : Google Scholar : PubMed/NCBI
24	Martín B, Sánchez-Carazo JL, Pérez-Ferriols A, Laguna C, Oliver V and Alegre V: Clinical experience with etanercept in the treatment of psoriasis. Actas Dermosifiliogr. 99:540–545. 2008.(In Spanish). View Article : Google Scholar : PubMed/NCBI
25	Sehgal VN, Pandhi D and Khurana A: Biologics in dermatology: An integrated review. Indian J Dermatol. 59:425–441. 2014. View Article : Google Scholar : PubMed/NCBI
26	Niculet E, Neculia GV, Tatu AL and Buzia OD: Curcumin-extraction, physical and chemical analysis, formulas and control. Basic methods for further research. Mater Plast. 55:672–675. 2018.
27	Nwabudike LC and Tatu AL: Using complementary and alternative medicine for the treatment of psoriasis: A step in the right direction. JAMA Dermatol. 155:6362019. View Article : Google Scholar : PubMed/NCBI
28	Căruntu C, Boda D, Dumitrașcu G, Constantin C and Neagu M: Proteomics focusing on immune markers in psoriatic arthritis. Biomarkers Med. 9:513–528. 2015. View Article : Google Scholar
29	Ilie MA, Căruntu C, Lixandru D, Tampa M, Georgescu SR, Constantin MM, Constantin C, Neagu M, Zurac SA and Boda D: In vivo confocal laser scanning microscopy imaging of skin inflammation: Clinical applications and research directions. Exp Ther Med. 17:1004–1011. 2019.PubMed/NCBI
30	Căruntu C, Boda D, Musat S, Căruntu A and Mandache E: Stress-induced mast cell activation in glabrous and hairy skin. Mediators Inflamm. 2014:1059502014. View Article : Google Scholar : PubMed/NCBI